190 related articles for article (PubMed ID: 30964093)
1. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
Yousuf SD; Ganie MA; Jeelani S; Mudassar S; Shah ZA; Zargar MA; Amin S; Wani IA; Rashid F
Indian J Med Res; 2018 Dec; 148(Suppl):S151-S155. PubMed ID: 30964093
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women.
Yousuf SD; Ganie MA; Urwat U; Andrabi SM; Zargar MA; Dar MA; Manzoor-Ul-Rehman M; Mudassar S; Rashid F
BMC Womens Health; 2023 Feb; 23(1):68. PubMed ID: 36793022
[TBL] [Abstract][Full Text] [Related]
3. Does the Oral Contraceptive Pill Increase Plasma Intercellular Adhesion Molecule-1, Monocyte Chemoattractant Protein-1, and Tumor Necrosis Factor-α Levels in Women with Polycystic Ovary Syndrome: A Pilot Study.
Yousuf SD; Rashid F; Mattoo T; Shekhar C; Mudassar S; Zargar MA; Ganie MA
J Pediatr Adolesc Gynecol; 2017 Feb; 30(1):58-62. PubMed ID: 27381237
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
6. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Sahu A; Tripathy P; Mohanty J; Nagy A
J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
[TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
8. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study.
Manzoor S; Ganie MA; Amin S; Shah ZA; Bhat IA; Yousuf SD; Jeelani H; Kawa IA; Fatima Q; Rashid F
Sci Rep; 2019 Jul; 9(1):10182. PubMed ID: 31308416
[TBL] [Abstract][Full Text] [Related]
10. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
Minozzi M; Costantino D; Guaraldi C; Unfer V
Gynecol Endocrinol; 2011 Nov; 27(11):920-4. PubMed ID: 21417594
[TBL] [Abstract][Full Text] [Related]
11. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Glintborg D; Altinok ML; Mumm H; Hermann AP; Ravn P; Andersen M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2584-91. PubMed ID: 24742124
[TBL] [Abstract][Full Text] [Related]
12. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
Adeniji AA; Essah PA; Nestler JE; Cheang KI
J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
[TBL] [Abstract][Full Text] [Related]
14. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
15. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
Velazquez EM; Mendoza SG; Wang P; Glueck CJ
Metabolism; 1997 Apr; 46(4):454-7. PubMed ID: 9109854
[TBL] [Abstract][Full Text] [Related]
16. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
17. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
[TBL] [Abstract][Full Text] [Related]
18. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
Burchall GF; Piva TJ; Ranasinha S; Teede HJ
Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
[No Abstract] [Full Text] [Related]
19. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Meyer C; McGrath BP; Teede HJ
Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
